AbSci’s Strategic Partnerships and Strong Financial Position Justify Buy Rating
Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on AbSci (ABSI – Research Report). The associated price ...
clinicaltrialsarena3d
Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment
Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment.
Buy Rating for X4 Pharmaceuticals Driven by Strategic Partnership and Strong Valuation
X4 Pharmaceuticals (XFOR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula ...